Citizens Jmp Forecasts Strong Price Appreciation for National Research (NASDAQ:NRC) Stock

National Research (NASDAQ:NRC) had its target price increased by investment analysts at Citizens Jmp from $26.00 to $27.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp‘s target price would indicate a potential upside of 24.14% from the stock’s previous close.

A number of other equities research analysts have also issued reports on NRC. Weiss Ratings lowered shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 9th. Zacks Research upgraded shares of National Research to a “hold” rating in a report on Monday, October 5th. Finally, Wall Street Zen lowered National Research from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $27.00.

National Research Stock Down 3.1%

NASDAQ NRC opened at $21.75 on Wednesday. The company has a fifty day simple moving average of $21.12 and a two-hundred day simple moving average of $19.15. National Research has a 12-month low of $11.43 and a 12-month high of $23.68.

National Research (NASDAQ:NRC) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.03. The company had revenue of $38.40 million during the quarter, compared to analyst estimates of $35.80 million. On average, research analysts expect that National Research will post 0.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Heartland Advisors Inc. increased its holdings in National Research by 374.3% during the 1st quarter. Heartland Advisors Inc. now owns 237,147 shares of the company’s stock valued at $4,027,000 after acquiring an additional 187,147 shares in the last quarter. Farmers & Merchants Investments Inc. lifted its position in National Research by 51.7% during the third quarter. Farmers & Merchants Investments Inc. now owns 501,731 shares of the company’s stock worth $10,632,000 after buying an additional 171,082 shares during the period. Fifth Third Bancorp acquired a new position in National Research during the first quarter worth approximately $1,531,000. Quantinno Capital Management LP grew its stake in National Research by 61.3% during the first quarter. Quantinno Capital Management LP now owns 62,329 shares of the company’s stock worth $1,058,000 after buying an additional 23,682 shares during the period. Finally, Empirical Finance LLC acquired a new position in shares of National Research during the second quarter worth $431,000. 47.26% of the stock is owned by hedge funds and other institutional investors.

National Research Company Profile

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.

Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.